SEC Form 4 · accession 0001012975-19-000028
Altimmune, Inc. · ALT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
M Scot Roberts
Officer — Chief Scientific Officer
Period of report
Jan 2, 2019
Accepted (ET)
Jan 4, 2019 · 4:58 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001326190
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (option to buy)F1 | $2.60 | Jan 2, 2019 | A | 30,000 | A | — | Jan 2, 2029 | Common Stock, par value $0.0001 | 30,000 | 30,000 | D |
Explanation of responses
- F1Twenty-five percent of the shares underlying the option become vested and exercisable on the first anniversary of the Grant Date and the remaining 75% of the shares underlying the option become vested and exercisable in substantially equal monthly installments over the 36 months following the one-year anniversary of the Grant Date, in each case, generally subject to the reporting person's continued service through the applicable vesting date.